Table 1. Clinical characteristics and outcome of PMF patients stratified according to their CALR type 1/type 1-like, CALR type 2/type 2-like and JAK2V617F mutational status.

Variables	CALR mutated			JAK2V617F mutated	P-value
	Type 1/1-like	Type 2/2-like	P		CALR versus JAK2V617F	CALR Type 1/1-like versus JAK2V617F	CALR Type 2/2-like versus JAK2V617F
N (% of total)	53 (13.4%)	21 (5.3%)	—	251 (63.4%)	—	—	—
Age in years; median (range)	53.3 (21–84)	61.2 (27–82)	0.210	66.7 (28–90)	<0.0001	<0.0001	0.027
Males; n (%)	25 (47.2%)	13 (61.9%)	0.253	159 (63.3%)	0.090	0.022	0.534
Hemoglobin, g/l; median (range)	112 (64–140)	108 (80–150)	0.958	120 (40–175)	0.637	0.362	0.704
Leukocytes, × 10⁹/l; median (range)	7.0 (1.6–18.9)	7.7 (4.2–18.1)	0.159	10.0 (1.9–96.2)	<0.0001	<0.0001	0.047
Platelets, × 10⁹/l; median (range)	441.5 (59–1563)	629.5 (22–1302)	0.112	308.0 (23–2011)	<0.0001	0.024	<0.0001
Circulating blasts ⩾1% n (%)	6 (12.8%)	5 (27.8%)	0.149	45 (18.7%)	0.356	0.227	0.252
Constitutional symptoms; n (%)	14 (26.4%)	4 (19.0%)	0.505	93 (37.1%)	0.106	0.093	0.074

Cytogenetic categories; n (%) 'N' evaluable=231
Abnormal Unfavorable karyotype	7 (22.6%)	3 (23.1%)	0.971	45 (30.6%)	0.267	0.286	0.171
High/very high	4 (12.9%)	2 (15.4%)	0.827	16 (10.9%)	0.858	0.474	0.444

IPSS risk group; n (%)
Low	26 (49.0%)	9 (43.0%)	0.170	58 (23.1%)	0.001	<0.0001	0.193
Intermediate-1	16 (30.2%)	4 (19.0%)		82 (32.7%)
Intermediate-2	9 (17.0%)	4 (19.0%)		56 (22.3%)
High	2 (3.8%)	4 (19.0%)		55 (21.9%)
Progression to leukemia; n (%)	3 (5.8%)	4 (19.0%)	0.08	17 (6.8%)	0.105	0.540	0.066
Death; n (%)	9 (17.0%)	10 (47.6%)	0.007	84 (33.5%)	0.017	0.011	0.142

Abbreviation: PMF, primary myelofibrosis. Bold values denote statistically significant difference.